Japanese urological association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan

International Journal of Urology

Volumn 15, Issue 9, 2008, Pages 763-768

  Ito, Kazuto ^a,e,g   Kakehi, Yoshiyuki ^b,e   Naito, Seiji ^c,e,f   Okuyama, Akihiko ^d,e,f   Imamura, Tomoaki ^e   Yasunaga, Hideo ^e   Akaza, Hideyuki ^e   Hinotsu, Shiro ^e   Arai, Yoichi ^e   Dokiya, Takushi ^e   Egawa, Shin ^e   Suzuki, Kazuhiro ^e   Koga, Hirofumi ^e   Masumori, Naoya ^e   Akakura, Koichiro ^e   Kawashima, Kiyotaka ^e   Okihara, Koji ^e  

^a GUNMA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e Japan Medical Association   (Japan)

^f Japanese Urological Association

^g GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; HUMAN; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

AGED; COHORT STUDIES; HUMANS; JAPAN; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 51349105395     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02125.x     Document Type: Review

References (27)

1. Ohno Y, Nakamura T, Murata K, Tsukuma H, Ajiki W, Oshima A. Prediction of the future incidence of cancer in Japan. In : Oshima A, Kuroishi T, Tajima K (eds). White Paper on Cancer and Statistics- Incidence/Mortality/Prognosis-2004. Shinohara-shuppan, Tokyo, 2004 201 17 In Japanese).
2. Kuroishi T, Hirose K, Tominaga Y, Aoki K, Tajima K. Prediction of the future mortality of cancer in Japan. In : Oshima A, Kuroishi T, Tajima K (eds). White Paper on Cancer and Statistics- Incidence/Mortality/ Prognosis-2004. Shinohara-shuppan, Tokyo, 2004 219 34 In Japanese).
3. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 2007 58 : 71 96.
4. Jemal A, Ward E, Wu X, Martin HJ, McLaughlin CC, Thun MJ. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol. Biomarkers. Prev. 2005 14 : 590 5.
5. Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer - Results from a prospective, population-based randomized controlled trial. Eur. Urol. 2007 51 : 659 64.
6. Bartsch G, Horninger W, Klocker H et al. Tyrol Prostate Cancer Demonstration Project: Early detection, treatment, outcome, incidence and mortality. J. Urol. 2007 177 (Suppl 583 4.
7. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J. Clin. 2006 56 : 11 25.
8. American Urological Association (AUA). Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Williston Park) 2000 14 : 267 72, 277 8, 280 passim.
9. U.S. Preventive Services Task Force (USPSTF). Recommendations and Rationale. Screening for Prostate Cancer Cited 22 Apr 2008.] Available from URL: http://www.ahcpr.gov/clinic/3rduspstf/prostatescr/prostaterr.htm
10. Kubota Y, Ito K, Imai K, Yamanaka H. Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate 2002 50 : 262 9.
11. Ito K, Yamamoto T, Miyakubo M et al. Lead time of prostate cancer detected in population-based screening for prostate cancer in Japan. J. Urol. 2007 178 : 1258 64.
12. Okihara K, Kitamura K, Okada K, Mikami K, Ukimura O, Miki T. Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan. Int. J. Urol. 2008 15 : 156 60.
13. Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000 355 : 1788 9.
14. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002 325 : 740 5.
15. Perron L, Moore L, Bairati I, Bernard PM, Meyer F. PSA screening and prostate cancer mortality. CMAJ 2001 166 : 586 91.
16. Coldman AJ, Phillips N, Pickles TA. Trends in prostate cancer incidence and mortality: An analysis of mortality change by screening intensity. CMAJ 2003 168 : 31 5.
17. La Rosa F, Stracci F, Minelli L, Mastrandrea V. Epidemiology of prostate cancer in the Umbria region of Italy: Evidence of opportunistic screening effects. Urology 2003 62 : 1040 4.
18. Threfall TJ, English DR, Rouse IL. Prostate cancer in West Australia: Trends in incidence and mortality from 1985 to 1996. Med. J. Aust. 1998 169 : 21 4.
19. Skarsgard D, Tonia J. Prostate cancer in Saskatchewan Canada, before and during the PSA era. Cancer Causes Control. 2000 11 : 79 88.
20. Majeed A, Babb P, Jones J, Quinn M. Trends in prostate cancer incidence, mortality and survival in England and Wales 1971-1998. BJU Int. 2000 85 : 1058 62.
21. Post PN, Kil PJ, Crommelin MA, Schapers RF, Coebergh JW. Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in Southeastern Netherlands, 1971-1995. Eur. J. Cancer 1998 34 : 705 9.
22. Brewster DH, Fraser LA, Harris V, Black RJ. Rising incidence of prostate cancer in Scotland: Increased risk or increased detection? BJU Int. 2000 85 : 463 73.
23. Ito K, Yamamoto T, Ohi M et al. Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology 2000 56 : 278 82.
24. Ito K, Yamamoto T, Ohi M et al. Cumulative probability of PSA increase above 4.0 ng/mL in population based screening for prostate cancer. Int J Cancer 2004 109 : 455 60.
25. Ito K, Yamamoto T, Ohi M et al. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/mL or less. Prostate 2003 57 : 8 13.
26. Ito K, Yamamoto T, Suzuki K, Kurokawa K, Yamanaka H. The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.0 ng/mL or less. J. Urol. 2004 171 : 656 60.
27. Kakehi Y, Naito S, Urological J. Association: Complication rates of ultrasound-guided prostate biopsy: A nation-wide survey in Japan. Int. J. Urol. 2008 15 : 319 21.